共 50 条
Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report
被引:4
|作者:
Sasaki, Taro
[1
]
Kawashima, Hiroyuki
[2
]
Ariizumi, Takashi
[2
]
Yamagishi, Tetsuro
[2
]
Oike, Naoki
[2
]
Umezu, Hajime
[3
]
Inagawa, Shyoichi
[4
]
Hotta, Tetsuo
[2
]
Endo, Naoto
[2
]
Ogose, Akira
[5
]
机构:
[1] Niigata Canc Ctr Hosp, Dept Orthoped Surg, Niigata, Niigata 9518510, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Div Orthoped Surg, Niigata, Niigata 9518510, Japan
[3] Niigata Univ, Med & Dent Hosp, Uonuma Inst Community Med, Div Pathol, Niigata, Niigata 9518510, Japan
[4] Niigata Univ, Med & Dent Hosp, Uonuma Inst Community Med, Div Radiol, Niigata, Niigata 9518510, Japan
[5] Niigata Univ, Med & Dent Hosp, Uonuma Inst Community Med, Dept Orthoped Surg, Niigata, Niigata 9518510, Japan
关键词:
denosumab;
leiomyosarcoma;
bone tumor;
osteoclast-like giant cells;
D O I:
10.3892/mco.2017.1489
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy.
引用
收藏
页码:30 / 33
页数:4
相关论文